Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Several other research analysts also recently issued reports on SYRS. JMP Securities downgraded Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Wedbush reaffirmed an “outperform” rating and set a $22.84 price target (down previously from $25.00) on shares of Syros Pharmaceuticals in a research note on Thursday, August 10th. Cowen and Company reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, August 9th. Cann reiterated a “buy” rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Finally, ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $26.37.

Syros Pharmaceuticals (SYRS) traded up 1.63% during midday trading on Wednesday, hitting $16.84. 179,653 shares of the stock were exchanged. Syros Pharmaceuticals has a one year low of $10.22 and a one year high of $24.38. The stock’s market cap is $442.22 million. The firm has a 50-day moving average price of $15.87 and a 200-day moving average price of $15.87.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.03. On average, equities research analysts anticipate that Syros Pharmaceuticals will post ($2.09) EPS for the current fiscal year.

WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/10/11/syros-pharmaceuticals-inc-syrs-downgraded-by-zacks-investment-research-to-sell.html.

In related news, insider Eric R. Olson sold 12,500 shares of Syros Pharmaceuticals stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $21.85, for a total transaction of $273,125.00. Following the completion of the sale, the insider now owns 12,500 shares in the company, valued at approximately $273,125. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric R. Olson sold 2,500 shares of Syros Pharmaceuticals stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $23.59, for a total value of $58,975.00. Following the sale, the insider now owns 2,500 shares of the company’s stock, valued at approximately $58,975. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,564 shares of company stock valued at $476,803. 33.60% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AWM Investment Company Inc. grew its holdings in Syros Pharmaceuticals by 155.8% in the 2nd quarter. AWM Investment Company Inc. now owns 121,624 shares of the company’s stock valued at $1,957,000 after buying an additional 74,074 shares during the period. California State Teachers Retirement System grew its holdings in Syros Pharmaceuticals by 131.3% in the 2nd quarter. California State Teachers Retirement System now owns 22,200 shares of the company’s stock valued at $357,000 after buying an additional 12,600 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Syros Pharmaceuticals by 11,253.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after buying an additional 10,466 shares during the period. Redmile Group LLC grew its holdings in Syros Pharmaceuticals by 2.2% in the 2nd quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after buying an additional 20,520 shares during the period. Finally, State Street Corp grew its holdings in Syros Pharmaceuticals by 176.7% in the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after buying an additional 108,250 shares during the period. Institutional investors own 59.61% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.